Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimepinostat in Children and Young Adults With Newly Diagnosed DIPG, Recurrent Medulloblastoma, or Recurrent HGG
NCT03893487Phase 1Completed
- Start
- Aug 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of fimepinostat in diffuse intrinsic pontine glioma (DIPG), medulloblastoma and glioma. Primary endpoint: Penetration of fimepinostat across the blood brain barrier. Started Aug 2019; status: completed.
02
Drugs
fimepinostat
03
Conditions
diffuse intrinsic pontine glioma (DIPG)medulloblastomaglioma
Beyond the preview
Go deeper on NCT03893487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893487.